China-Brazil Medical and Health Innovation Cooperation Forum｜ KERUICHI Chairman Che Haibo was invited to deliver a keynote speech

On March 12, the China-Brazil Medical and Health Innovation Cooperation Forum, jointly guided by the Shanghai Biomedical Science and Technology Development Center and the Shanghai Biomedical Industry Promotion Center and hosted by AstraZeneca, was grandly held at the AstraZeneca Global R&D China Center.

On March 12, the China-Brazil Medical and Health Innovation Cooperation Forum, jointly guided by the Shanghai Biomedical Science and Technology Development Center and the Shanghai Biomedical Industry Promotion Center and hosted by AstraZeneca, was grandly held at the AstraZeneca Global R&D China Center. Mr. Marco Krieger, Vice President of Health Production and Innovation of the FIOCRUZ Osvaldo Cruz Foundation, a Brazilian public health institution, and Dr. Mauricio Medeiros, Director and CEO of the Latin American Institute of Biological Technology. 

Government and enterprise representatives from the industry jointly conducted in-depth sharing and discussions on China’s innovation “going abroad” and cooperation opportunities in Brazil. Che Haibo, founder and chairman of KERUICHI share in "Key registration points for Chinese medical device companies to go to Brazil", shares the opportunities for innovation companies to go to Brazil and seize the Latin American business. stories and experiences.

Chairman Che Haibo took KERUICHI 's product of interventional microcatheter kit that was registered and approved by Brazil's ANVISA as an example and introduced the registration keys for Chinese medical device companies to go overseas in Brazil from various aspects such as registration regulations, process steps, registration strategies, and document preparation..

Chairman Che Haibo said that overseas registration is a systematic cross-departmental collaboration project. Within creativity, the RA department is responsible for the project strategy and specific work arrangements; the R&D department and the quality department are responsible for conducting various verification and outputting reports in accordance with ANVISA requirements; the marketing department is responsible for formulating market planning and designing special packaging for the Brazilian market.

During the process of project advancement, ''KERUICHI Team” always aimed to obtain ANVISA registration approval as its ultimate goal, conducted in-depth research on the needs and regulatory requirements of the Brazilian market, and incorporated these factors into the registration strategy considerations; in the process of advancing the plan, it actively Seek feedback and strives to ensure that relevant ANVISA guidelines are met. More importantly, the KERUICHI focuses on close cooperation and efficient communication among team members. They work together, leveraging their professional strengths and working collaboratively to achieve the ultimate goal.

Mr. Che Haibo emphasized that there are several highlights of Brazil's ANVISA registration worthy of attention: from zero to ANVISA approval only takes 10 working days; the total registration preparation time is only 2 months. The final successful approval not only demonstrates the strength of the company's products and technical services, but also embodies the persistent pursuit of excellence and the philosophy of starting with the end in mind by the KERUICHI team.

In the past ten years, China's innovative drugs and medical devices have both improved in quantity and quality. Against the background of the maturation of the local market and intensified competition, exploring overseas markets and promoting international layout is the key to the sustainable development of Chinese pharmaceutical companies.

The only way to go! KERUICHI will continue to adhere to the concept of "based on therapeutic reading, reconstruct the local immune ecology, and build targeted treatment devices and drug delivery systems for sequential cell apoptosis and death", connecting clinical needs and engineering technology at zero distance, Providing intelligent tools for physician to deal with clinical challenges, helping more domestic patients relieve pain and prolong life, while further actively exploring overseas markets, assisting innovative development in the global medical and health field, and making greater contributions to building a community with a shared future for mankind.